Form 4: Vir Biotechnology Executive Sells Shares Under 10b5-1 Plan

A Vir Biotechnology executive sold 2,385 shares of common stock for $5.16 per share under a pre-arranged trading plan.

Summary

• Vanina de Verneuil, EVP, General Counsel, and Corporate Secretary of Vir Biotechnology, Inc., reported a sale of company common stock.
• The transaction involved the disposition of 2,385 shares.
• The shares were sold at a price of $5.16 per share.
• The sale was executed on November 5, 2025.
• Following this transaction, the reporting person beneficially owns 78,210 shares of common stock.
• The sale was conducted under a Rule 10b5-1 trading plan, which was adopted on August 5, 2024.

Sentiment

Score: 5

Explanation: The transaction is a routine insider stock sale executed under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a scheduled liquidity event rather than a change in management's outlook on the company's future.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May observe a slight increase in available shares on the market, though the impact is minimal given the small volume relative to total outstanding shares. The 10b5-1 plan mitigates concerns about insider sentiment.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled insider stock sale under a 10b5-1 plan. Such transactions are typically for personal financial planning and do not reflect a change in the company's fundamental outlook or performance. Therefore, this specific filing provides no new information that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Vir Biotechnology, VIR, Form 4, Insider Trading, Stock Sale, Executive Compensation, 10b5-1 Plan, Vanina de Verneuil, Common Stock